Abstract: A multi-band high-frequency circuit for performing wireless communications among pluralities of communication systems having different communication frequencies, comprising a high-frequency switch circuit comprising switching elements for switching the connection of pluralities of multi-band antennas to transmitting circuits and receiving circuits; a first diplexer circuit disposed between the high-frequency switch circuit and transmitting circuits for branching a high-frequency signal into frequency bands of the communication systems; a second diplexer circuit disposed between the high-frequency switch circuit and receiving circuits for branching a high-frequency signal into frequency bands of the communication systems; the first and second diplexer circuits each comprising a lower-frequency filter circuit and a higher-frequency filter circuit, a bandpass filter circuit being used as the lower-frequency filter circuit in the second diplexer circuit, or disposed between the lower-frequency filter circuit in t

Abstract: The present invention provides a TNF-? production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-? production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-?, the agent containing a kavalactone as an active ingredient.

Abstract: The present invention provides a TNF-? production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-? production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-?, the agent containing a kavalactone as an active ingredient.

Abstract: The transport apparatus is provided with a path that extends past a plurality of article transferring locations, a plurality of article transporting vehicles that run on the path, a travel driving means provided on each of the article transporting vehicles for controlling movement of the article transporting vehicle, and a ground-side controller for managing operation of the plurality of article transporting vehicles by managing the travel driving means, wherein the ground-side controller is capable of transmitting run command information and stop command information, relating to each of the article transporting vehicles, to their corresponding travel driving means, and wherein the travel driving means drives and stops the article transporting vehicles based on the run command information and the stop command information from the ground-side controller.

Abstract: Functional food including milk products from which an antihypertensive effect is obtained in a more natural way, more specifically functional food of which ACE inhibitory activity is enhanced by adding EMC preferably with ACE inhibitory activity of 9,000 units or more is provided. ACE inhibitory activity of this functional food is made 5,000 units or more per daily standard intake of the product. For example, in case of processed cheese, ACE inhibitory activity is made 350 units per gram or more assuming daily intake to be approximately 15 g.

Abstract: Processed cheeses with an antihypertensive effect greater than that of conventional cheese are provided in order to obtain a sufficient antihypertensive effect with a small intake. Specifically, processed cheeses with ACE inhibitory activity of 350 units per gram or more are manufactured using natural cheese such as cheddar cheese produced in New Zealand and Emmental cheese produced in Switzerland with ACE inhibitory activity of 420 units per grams or more. In addition, it is preferable to use low salt or unsalted natural cheese as a raw material, and use potassium salt as molten salt in order to make sodium content 990 mg or less per 100 g of processed cheese.

Abstract: In a process of hydrocracking heavy oil with a catalyst in petroleum refining, asphaltene contained in heavy oil, and impurities including heavy metals such as nickel and vanadium, are efficiently removed with activated carbon, whereby the reduction in catalyst activity or formation of coke by the impurities can be prevented. The invention provides a hydrocracking catalyst comprising activated carbon extrudate as a carrier activated with steam and having a high distribution of pores having pore sizes in the range of 20 to 200 nm.

Abstract: The present invention forms a mixture basically consisting of threonine, proline, glycine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, aspartic acid, serine, glutamic acid, alanine, methionine, histidine and arginine as a unit, by which a body temperature raising effect was observed. The similar body temperature raising effect was observed when carnitine and/or tryptophan is added to the unit. These groups were found to be amino acid mixture-containing agents capable of raising body temperature for food or drink use or medical use. The agents have excellent body temperature raising effect, thereby having the functions of reduction of accumulated body fat, alleviation of excess sensitivity to cold, warming of a cold body, and the like.

Abstract: Provided is a preventive or remedy for diseases caused by a cerebrovascular disturbance, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic compound represented by the following formula (1): [wherein, R1, R2 and R3 each independently represents H or CH3 and X represents a C10-28 alkylene or alkenylene group].

Abstract: The present invention provides a TNF-&agr; production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-&agr; production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-&agr;, the agent containing a kavalactone as an active ingredient.

Abstract: The present invention provides an apparatus and a method for finding out a specific portion for recording the activity accurately and easily in recording the activity of an organism specimen in vivo. An organism specimen (3) with a fluorescent substance expressed at the specific portion (3a) is prepared. An optical fiber (7) is inserted into the organism specimen (3). An excitation rays (4) irradiate the inside of the organism specimen (3) through the optical fiber (7) by a first optical system (9) of a fluorescence microscope (6). The fluorescence (5) by the excitation rays (4) is observed through the optical fiber (7) by a second optical system (10) of the fluorescence microscope (6). In this case, the optical fiber (7) is inserted at the specific portion (3a) of the organism specimen or in the vicinity thereof.

Abstract: The present invention provides a TNF-&agr; production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-&agr; production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-&agr;, the agent containing a kavalactone as an active ingredient.

Abstract: The present invention provides a TNF-&agr; production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-&agr; production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-&agr;, the agent containing a kavalactone as an active ingredient.

Abstract: An anti-ulcer composition is provided, which comprises as an active ingredient at least one of MK protein, its derivative having biological activity of MK protein, and their fragment having biological activity of MK protein, and a pharmaceutically acceptable carrier. The composition exhibits an effect for treating ulcer by promoting autotherapy without recurrence of ulcer.

Abstract: A process for producing a semi-insulating InP single crystal and a semi-insulating InP single crystal are disclosed. The process comprises: a first step heat-treatment for heating an undoped InP single crystal having a concentration of a residual impurity of 0.05 ppmw or less containing at least one of Fe, Co and Cr, at a temperature of not less than 930.degree. C. and less than 1000.degree. C. in an atmosphere of phosphorous vapor pressure in the ampoule which is not less than a dissociation pressure of InP in equilibrium at the temperature and which is not more than 15 atm; and a second step heat-treatment for thereafter heating the InP single crystal at a temperature of not less than 662.degree. C. and less than 900.degree. C. in an atmosphere of phosphorous vapor pressure in the ampoule which is not less than 5 atm nor more than 50 atm. The semi-insulating InP single crystal substrate has a uniformity of mobility not more than 10% on the surface of the substrate.

Abstract: The present invention discloses a method for the treatment of liver diseases, comprising administering an effective amount of an aminoalcohol of the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 represents a hydrogen atom or a phosphono group, R.sup.2 represents a hydrogen atom or a group --(CH.sub.2).sub.n --OR.sup.1, and n represents an integer between 2 and 5 inclusive. The present invention also relates to the use of the compound in the manufacture of a remedy for the treatment of liver diseases. This compound exhibits hepatocyte proliferation activity and liver disorder restoring effect, and thus is useful for the treatment of acute hepatitis, chronic hepatitis, hepatic cirrhosis, etc.

Abstract: The present invention discloses a method for the treatment of liver diseases, comprising administering an effective amount of an aminoalcohol of the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 represents a hydrogen atom or a phosphono group, R.sup.2 represents a hydrogen atom or a group--(CH.sub.2).sub.n --OR.sup.1, and n represents an integer between 2 and 5 inclusive. The present invention also relates to the use of the compound in the manufacture of a remedy for the treatment of liver diseases. This compound exhibits hepatocyte proliferation activity and liver disorder restoring effect, and thus is useful for the treatment of acute hepatitis, chronic hepatitis, hepatic cirrhosis, etc.

Abstract: There is provided a partition wall which is characterized in that studs are secured to upper and lower runners fitted to a substrate in a zigzag arrangement or as common studs; that basic face materials are fitted to the skeleton through sound insulation materials so that the face materials are arranged, in parallel, on both outer sides of the studs, while the studs are internally positioned; and that a hard gypsum sheet comprising fibers dispersed in the gypsum core thereof is arranged on the corresponding outer side of each basic face material. This partition wall is particularly suitable for use as a dry party wall, has satisfactory characteristic properties such as fire protecting properties, sound insulation properties, deformation-follow-up properties, out-of-plane flexural rigidity and hardness. The wall comprises gypsum based construction materials as the top end boards and thus the weight and wall thickness thereof can be reduced.

Abstract: A process for growing a multielement compound single crystal, includes the steps of placing a crucible holding a raw multielement compound of a predetermined set of composition ratios Y in a vertical crystal growing furnace having a heater, melting the raw multielement compound held in the crucible with the heater to produce a melt of the raw multielement compound in the crucible, controlling the output of the heater to grow a multielement compound single crystal of a predetermined set of composition ratios X from the melt so that the melt is solidified successively upwards from part of the melt in contact with the bottom of the crucible, and feeding to the melt as a solute at least one element of the raw multielement compound from above the level of the melt in the crucible so as to maintain the predetermined set of composition ratios X of the solute during growth of the multielement compound single crystal. The process can keep constant the composition of the grown multielement compound single crystal.

Abstract: A process for growing a multielement compound single crystal, includes the steps of placing a crucible holding a raw multielement compound of a predetermined set of composition ratios Y in a vertical crystal growing furnace having a heater, melting the raw multielement compound held in the crucible with the heater to produce a melt of the raw multielement compound in the crucible, controlling the output of the heater to grow a multielement compound single crystal of a predetermined set of composition ratios X from the melt so that the melt is solidified successively upwards from part of the melt in contact with the bottom of the crucible, and feeding to the melt as a solute at least one element of the raw multielement compound from above the level of the melt in the crucible so as to maintain the predetermined set of composition ratios X of the solute during growth of the multielement compound single crystal. The process can keep constant the composition of the grown multielement compound single crystal.